Defining new therapeutic targets and developing new therapies are among the goals of the 2016–2020 ACR National Research Agenda. So, too, is understanding early disease states, defining triggers of autoimmunity and examining disparities in access to medication and treatment.1 Charting a Course Every five years, the Committee on Research (COR) is tasked with helping chart the…
Letters: Criticism for Complementary and Alternative Medicine Therapies in Rheumatoid Arthritis
One reader calls claims about the effectiveness of CAM to treat RA misleading; author notes proving the efficacy of alternative treatments remains challenging
Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors
Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease
Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways
Beyond biologic agents, scientists study cytokines, chemokines, and the interface between inflammatory and neural/secretory pathways
Biologic Logic: Making Sense of Current Therapies for Rheumatic Diseases
Continuing the ARHP 2009 Audioconference/Webcast series, Daniel F. Battafarano, DO, FACP, FACR, will discuss the use of biologic therapy in the treatment of rheumatology patients on February 10 from noon to 1:00 pm ET. During the session, Dr. Battafarano will review basic immunology, inflammation, and relevant cytokines for common rheumatic diseases. In addition, he will describe the current biologic therapies and their relationship to rheumatic disease outcomes, and identify future biologic strategies for therapy.